Triple

T23186580
Position Surface form Disambiguated ID Type / Status
Subject George D. Yancopoulos E579607 entity
Predicate notableWork P4 FINISHED
Object Regeneron’s COVID‑19 antibody cocktail (REGEN‑COV / casirivimab and imdevimab) — NE NERFINISHED

How this triple was built (2 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Regeneron’s COVID‑19 antibody cocktail (REGEN‑COV / casirivimab and imdevimab) | Statement: [George D. Yancopoulos, notableWork, Regeneron’s COVID‑19 antibody cocktail (REGEN‑COV / casirivimab and imdevimab)]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Regeneron’s COVID‑19 antibody cocktail (REGEN‑COV / casirivimab and imdevimab)
Context triple: [George D. Yancopoulos, notableWork, Regeneron’s COVID‑19 antibody cocktail (REGEN‑COV / casirivimab and imdevimab)]
  • A. REGN-COV2 chosen
    REGN-COV2 is a monoclonal antibody cocktail designed to prevent and treat COVID-19 by targeting the SARS-CoV-2 virus.
  • B. SARS-CoV-2 spike glycoprotein
    The SARS-CoV-2 spike glycoprotein is the viral surface protein that mediates coronavirus entry into human cells and is the primary target of neutralizing antibodies and many COVID-19 vaccines.
  • C. Inmazeb (in combination with atoltivimab and odesivimab)
    Inmazeb is an FDA-approved antibody cocktail therapy used to treat infections caused by Zaire ebolavirus.
  • D. mRNA-1273
    mRNA-1273 is a messenger RNA–based COVID-19 vaccine that instructs cells to produce the SARS-CoV-2 spike protein to elicit an immune response.
  • E. odesivimab
    Odesivimab is a monoclonal antibody used as part of an antibody cocktail therapy for the treatment of Ebola virus infection.
  • F. None of above.
  • G. Unsure - the case is ambiguous/there is not enough information to decide.

Provenance (2 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69e245ff8000819090d12008805315b7 completed April 17, 2026, 2:38 p.m.
NER Named-entity recognition batch_69f18fd3aaa08190b9cf7afe4ee5a38d completed April 29, 2026, 4:57 a.m.
Created at: April 17, 2026, 4:05 p.m.